Well then Tasly and Mesoblast can choose to expand the license agreement or another, probably Chinese company can take up a license agreement for remestemcel-L.
Tasly makes much more sense though especially as they already know about Mesoblast manufacturing, have the expertise to do it and have a massive reach across hospitals in China. This is a slide summarising IP from the recent, 2020 Global Biotech Showcase.
All depends if by a standardised MSC product they will accept one made by a local business, with royalties flowing off shore.
Well then Tasly and Mesoblast can choose to expand the license...
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
-0.025(2.17%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.16 | $1.11 | $7.363M | 6.488M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 94863 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 5000 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |